Neurosense Therapeutics is trading at $0.37 (-7.06%) amid broader biotech and market weakness; no confirmed August 20, 2026 company-specific announcement explains the decline.
- Recent concerns include Phase 3 funding delays, Nasdaq compliance, and a proposed 1-for-4 to 1-for-40 reverse split.
- Biotech is down 2.47%, while the Nasdaq is down 0.88%, suggesting sector and risk-off pressure are contributing.